Pomalyst and Shock - a phase IV clinical study of FDA data

Summary:

Shock is reported as a side effect among people who take Pomalyst (pomalidomide), especially for people who are male, 60+ old, have been taking the drug for 6 - 12 months also take Ninlaro, and have Multiple myeloma.

The phase IV clinical study analyzes which people have Shock when taking Pomalyst. It is created by eHealthMe based on reports of 80,394 people who have side effects when taking Pomalyst from the FDA, and is updated regularly.

What is Pomalyst?

Pomalyst has active ingredients of pomalidomide. eHealthMe is studying from 80,400 Pomalyst users. Check the latest studies of Pomalyst.

What is Shock?

Shock (a life-threatening condition with symptoms like low blood pressure, weakness, shallow breathing, cold, clammy skin) is found to be associated with 1,216 drugs and 1,753 conditions by eHealthMe. Check the latest studies of Shock.

On Jul, 19, 2026

80,394 people reported to have side effects when taking Pomalyst.
Among them, 20 people (0.02%) have Shock.

Among these 20 people:

How long have people been on Pomalyst when they have Shock? *

What is the gender of people who have Shock when taking Pomalyst? *

female: 35 %
male: 65 %

What is the age of people who have Shock when taking Pomalyst? *

What are other drugs people take besides Pomalyst? *

What are other side effects people have besides Shock? *

Weakness: 6 people, 30.00%
Dyspnea (difficult or laboured breathing): 6 people, 30.00%
Fatigue (feeling of tiredness): 5 people, 25.00%
Thrombocytopenia (decrease of platelets in blood): 5 people, 25.00%
Sinusitis (inflammation of sinus): 5 people, 25.00%
Seizures (abnormal excessive or synchronous neuronal activity in the brain): 5 people, 25.00%
Hypercoagulation (increased tendency for clotting of the blood): 5 people, 25.00%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 4 people, 20.00%
Nasal Congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels): 4 people, 20.00%
Inner Ear Disorder: 3 people, 15.00%

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 17 people, 85.00%
Pain: 1 person, 5.00%
Monoclonal Gammopathy: 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Pomalyst and have Shock?

- Check whether Shock is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Pomalyst:

Pomalyst (80,400 reports)

Shock treatments and more:

Shock (28,534 reports)

Browse all side effects of Pomalyst:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Shock:

Shock (1,216 drugs)

Browse all the conditions that are associated with Shock:

Shock (1,753 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on pomalidomide (the active ingredients of Pomalyst) and Pomalyst (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.